[Antitumor activity of thevetoside alone and in combination with chlormethine in vivo].
Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with i.p. TS 1.5 mg.kg-1.d-1 alone or in combination with chlormethine (Chl) 0.3, 0.5, or 1.0 mg.kg-1.d-1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48.7%-56.7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82.4% to > 122.1%. For solid tumors, the combined administration gave inhibition rates of 65.6%-72.5%.
Zhang
X W
XW
Department of Pharmacology, Fujian Medical College, Fuzhou, China.
Huang
Z Q
ZQ
Li
C C
CC
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002301:Cardiac Glycosides / Q000008:administration & dosage*; D008466:Mechlorethamine / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D002301:Cardiac Glycosides; C016139:thevetoside; D008466:Mechlorethamine